BMYB34:BVMF
Bristol-Myers Squibb Company BDR
၃၃၁.၉၀ R$
arrow_upward
+၀.၆၅%(+၂.၁၅) 1D
စက် ၃၀, GMT-၃ ၁၁:၃၁:၂၅ · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMYB34...
Mkt. cap
ဋေ ၁.၂၁ သ
Avg. vol.
၃.၀၀
Volume
၀.၀၀
52-wk high
၃၄၇.၁၅ R$
52-wk low
၂၂၁.၇၂ R$
Shares outstanding
၂၀၄.၂၇ ဋေ
No. of employees
၃ သောင်း
Mkt. cap
ဋေ ၁.၂၁ သ
Avg. vol.
၃.၀၀
Volume
၀.၀၀
52-wk high
၃၄၇.၁၅ R$
52-wk low
၂၂၁.၇၂ R$
Shares outstanding
၂၀၄.၂၇ ဋေ
No. of employees
၃ သောင်း
News stories
From web sources and news partners
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၃၉ မိနစ်
Bristol Myers Squibb stock pre-market at EUR 52.73
The Motley Fool
·
ပြီးခဲ့သည့် ၁ ရက်
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
MarketBeat
·
ပြီးခဲ့သည့် ၂ ရက်
Bristol Myers Squibb (NYSE:BMY) Stock Price Target Raised at Rothschild & Co Redburn
The Globe and Mail
·
ပြီးခဲ့သည့် ၂ ရက်
Bristol-Myers Squibb (BMY) Receives a Buy from J.P. Morgan
Profile
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2025, 69% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
About Bristol-Myers Squibb Company BDR
CEOChris Boerner
Employees၃.၂၅ သောင်း
Founded၁၈၈၇
Headquartersနယူးယောက်မြို့, နယူးယောက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitebms.com